Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.76 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.76 |
| ▸ | PSMB1 | P20618 | 8/20 | 0.70 |
| ▸ | PSMB5 | P28074 | 8/20 | 0.70 |
| ▸ | PSMB2 | P49721 | 5/20 | 0.70 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.68 |
| ▸ | LTA4H | P09960 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1359959 | 1.00 | ESR1 (0.76) | ESR1ESR2PSMB1PSMB5PSMB2 | |
| SCHEMBL2475993 | 0.98 | ESR1 (0.75) | ESR1ESR2PSMB1PSMB5PSMB2 | |
| SCHEMBL13649149 | 0.95 | ESR1 (0.70) | ESR1ESR2PSMB1PSMB5PSMB2 | |
| SCHEMBL3573974 | 0.91 | HRH3 (0.75) | ESR1ESR2HRH3 | |
| SCHEMBL5174035 | 0.91 | PSMB1 (0.68) | ESR1ESR2PSMB1PSMB5PSMB2 | |
| SCHEMBL15492001 | 0.91 | HRH3 (0.66) | ESR1ESR2PSMB1PSMB5PSMB2 | |
| SCHEMBL5649675 | 0.90 | PSMB1 (0.82) | ESR1ESR2PSMB1PSMB5PSMB2 | |
| SCHEMBL4688676 | 0.89 | HRH3 (0.72) | ESR1ESR2HRH3KDM4E | |
| SCHEMBL7367096 | 0.88 | HRH3 (0.72) | HRH3 | |
| SCHEMBL31402365 | 0.87 | ESR1 (0.62) | ESR1ESR2PSMB1PSMB5PSMB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981887-B2 | Benzothiophene estrogen receptor modulators | G1 THERAPEUTICS, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200216406-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS | G1 THERAPEUTICS, INC. (US) | 2020-07-09 | — | — | US | disclosed |
| US-10633362-B2 | Benzothiophene estrogen receptor modulators | G1 THERAPEUTICS, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190119243-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS | G1 THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-10208011-B2 | Benzothiophene estrogen receptor modulators | G1 THERAPEUTICS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| EP-3192795-A1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | The Board of Trustees of the University of Illionis (US) | 2017-07-19 | — | — | EP | disclosed |
| US-8476300-B2 | Selective estrogen receptor modulator for the treatment of osteoarthritis | ELI LILLY AND COMPANY (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476300-B2 | Selective estrogen receptor modulator for the treatment of osteoarthritis | ELI LILLY AND COMPANY (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476300-B2 | Selective estrogen receptor modulator for the treatment of osteoarthritis | ELI LILLY AND COMPANY (US) | 2013-07-02 | — | — | US | disclosed |
| EP-2604601-A1 | HETERO RING COMPOUND | Astellas Pharma Inc. (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-5969142-A | OXIDIZING SULFUR ATOM OF SUBSTITUTED BENZOTHIOPHENE, REACTING PRODUCT WITH NUCLEOPHILIC GROUP, REDUCING PRODUCT TO DESIRED COMPOUND | ELI LILLY AND COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
| US-5919800-A | INHIBITING ENDOMETRIOSIS BY ADMISTERING (6-HYDROXY-3-(4-(2-(1-PIPERIDINYL)ETHOXY)PHENOXY)-2-(4-METHOXYPHENYL))BENZO B)THIOPHENE OR THE HYDROCHLORIDE SALT THEREOF | ELI LILLY AND COMPANY (US) | 1999-07-06 | — | — | US | disclosed |
| US-5856339-A | POST-MENOPAUSAL SYNDROME, AND UTERINE FIBROID DISEASE, ENDOMETRIOSIS, AND AORTAL SMOOTH MUSCLE CELL PROLIFERATION. | ELI LILLY AND COMPANY (US) | 1999-01-05 | — | — | US | disclosed |
| US-5856341-A | INHIBITING BONE LOSS OR BONE RESORPTION, PARTICULARLY OSTEOPOROSIS, CARDIOVASCULAR-RELATED PATHOLOGICAL CONDITIONS INCLUDING HYPERLIPIDEMIA, ESTROGEN-DEPENDENT CANCER | ELI LILLY AND COMPANY (US) | 1999-01-05 | — | — | US | disclosed |
| US-5856340-A | 2-PHENYL-3-/ALKOXYPHENOXY OR PHENYLTHIO/BENZOTHIOPHENES | ELI LILLY AND COMPANY (US) | 1999-01-05 | — | — | US | disclosed |
| WO-1998045287-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 1998-10-15 | — | — | WO | disclosed |
| WO-1998045286-A1 | PREVENTION OF BREAST CANCER WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 1998-10-15 | — | — | WO | disclosed |
| WO-1998045288-A1 | TREATMENT OR PROPHYLAXIS OF PROSTATIC CANCER AND BENIGN PROSTATIC HYPERPLASIA WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 1998-10-15 | — | — | WO | disclosed |
| US-5723474-A | TREATING POST-MENOPAUSAL SYNDROME, UTERINE FIBROID DISEASE, ENDOMETRIOSIS, AND AORTAL SMOOTH MUSCLE CELL PROLIFERATION; ANTIESTROGENS | ELI LILLY AND COMPANY (US) | 1998-03-03 | — | — | US | disclosed |
| EP-0729956-A1 | Benzothiophene compounds, intermediates, compositions, and methods | ELI LILLY AND COMPANY (US) | 1996-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981887-B2 | Benzothiophene estrogen receptor modulators | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885PSMB1 2280/4885 |
| US-10208011-B2 | Benzothiophene estrogen receptor modulators | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885PSMB1 2280/4885 |
| US-20200216406-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885PSMB1 2280/4885 |
| US-10633362-B2 | Benzothiophene estrogen receptor modulators | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885PSMB1 2280/4885 |
| US-20190119243-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885PSMB1 2280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.